A Safe and Efficient 7-Week Immunotherapy Protocol With Aluminum Hydroxide Adsorbed Bee Venom

Hymenoptera venom allergy is a frequent cause of anaphylactic reactions in Europe. Even though venom immunotherapy (VIT) is an effective, causal treatment protecting 77–84% of patients treated with honeybee venom, and 91–96% of patients receiving vespid venom from future systemic sting reactions (SSR), poor therapy adherence has been observed in Austria. Current conventional up-dosing protocols are still time-consuming for patients and, therefore, we initiated a prospective clinical trial evaluating the safety and efficacy of an accelerated up-dosing protocol with 8 weekly injections in 7 weeks to enhance the acceptance of this successful treatment. We could show that our 7-week outpatient protocol proved to be safe, even in patients with cardiovascular disease and antihypertensive treatment. The protocol is practical as well as efficient in terms of time and costs for patients and medical staff, which will lead to better patient acceptance of VIT. This dataset contains complete data used for analysis.